Clinical trials: Mania
Bipolar Disorder
Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents
This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.
- Trial name
- TEAM (NCT00057681)
- Testing
- Lithium carbonate, Valproate, Risperidone
- Where
- 5 sites in United States
- Volunteers
- 379 people
- Sponsor
- Washington University School of Medicine
Bipolar Disorder, Mania
Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar Disorder
The main objective of this study is to assess the effectiveness and safety of lamotrigine in the treatment of youth with bipolar and bipolar spectrum disorder.
- Trial name
- NCT00181844
- Testing
- lamotrigine
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Massachusetts General Hospital
Bipolar Disorder, Cannabis-Related Disorder
Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania
The objectives of this study are to determine whether this treatment may be useful for reducing cannabis consumption; reducing symptoms of bipolar mania; and weight mitigation therapy for individuals on psychopharmacotherapy.
- Trial name
- NCT00393978
- Testing
- Quetiapine and Topiramate
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Cincinnati
Bipolar Disorder
A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania
The purpose of this clinical research study is to learn if outpatients with bipolar mania who are partially nonresponsive to lithium or valproate monotherapy can achieve stable symptoms on a combination treatment of aripiprazole…
- Trial name
- NCT00261443
- Testing
- Lithium or Valproate with Aripiprazole
- Where
- 83 sites in United States, Brazil and 7 more
- Volunteers
- 1,270 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder
To assess the acute and long-term bimodal efficacy of QTP, as an adjunct to ongoing treatment with lithium (Li) or divalproex (DIV) or lamotrigine (LAM) or any combination of the three thereof, in a group of patients with an…
- Trial name
- NCT01195363
- Testing
- quetiapine SR
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Acute Mania, Bipolar Disorder, Manic
Ziprasidone And Olanzapine's Outcomes In Mania
The purpose of this study is to compare the efficacy and tolerability of ziprasidone versus olanzapine in the treatment of acute mania.
- Trial name
- ZOOM (NCT00329108)
- Testing
- ziprasidone hydrochloride, olanzapine
- Where
- 19 sites in Germany, Greece and 3 more
- Volunteers
- 29 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar I Disorder, Acute Mania
A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.
This study evaluated the safety and evaluate the safety and tolerability of open-label brexpiprazole (2 - 4 mg/day, with a starting dose of 2 mg/day) for the treatment of adult subjects with bipolar I disorder.
- Trial name
- NCT03287869
- Testing
- Brexpiprazole
- Where
- 73 sites in United States, Bulgaria and 4 more
- Volunteers
- 381 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
This study will assess the effects of bipolar disorder on brain activity and will determine if medication changes the brain activity in people with bipolar disorder.
- Trial name
- NCT00596622
- Testing
- Lithium
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Indiana University
Bipolar Disorder
Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)
The purpose of this study is to assess the safety and tolerability of ziprasidone during long-term open-label administration in children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed)
- Trial name
- NCT00265330
- Testing
- Ziprasidone oral capsules
- Where
- 41 sites in United States
- Volunteers
- 169 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar Disorder, Schizoaffective Disorder
Effects of Pentazocine Versus Lorazepam on Manic Symptoms
Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals. To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind study.
- Conditions
- Bipolar Disorder, Schizoaffective Disorder, Manic Disorder, Mania
- Trial name
- NCT00431184
- Testing
- Pentazocine, Lorazepam
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mclean Hospital
Bipolar I Disorder, Schizophrenia
Study in Adolescents With Schizophrenia or Bipolar Disorder
Open-label safety study of oral olanzapine treatment in adolescents, aged 13 to 17 years, with bipolar I disorder (manic or mixed episodes) or schizophrenia.
- Trial name
- NCT00982020
- Testing
- Olanzapine, Standard behavioral weight intervention, Intense behavioral weight intervention
- Where
- 14 sites in United States, Poland and 2 more
- Volunteers
- 203 people
- Sponsor
- Eli Lilly and Company
Acute Mania
Adult Bipolar Mania
The purpose of this study is to determine if lithium 600-1800 mg/day is effective when added to quetiapine fumarate extended release (quetiapine XR or SEROQUEL® XR) 400-800 mg/day in treating acute mania and if so, how it…
- Trial name
- NCT00931723
- Testing
- Quetiapine fumarate XR, Lithium
- Where
- 65 sites in Belgium, Bulgaria and 7 more
- Volunteers
- 356 people
- Sponsor
- AstraZeneca
Bipolar I Disorder, Manic Episode
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder
To demonstrate the efficacy of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in participants with a diagnosis of bipolar I disorder.
- Trial name
- NCT03259555
- Testing
- Brexpiprazole
- Where
- 48 sites in United States, Bulgaria and 2 more
- Volunteers
- 322 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder
This study will determine the efficacy and safety of combination therapy with divalproex and lithium for treating mania in people with rapid cycling bipolar disorder and a substance abuse disorder.
- Trial name
- NCT00194129
- Testing
- Lithium, Divalproex
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University Hospitals Cleveland Medical Center
Mania, Hypomania
Bipolar Intervention Study: Cognitive Interpersonal Therapy
There is a need to develop a better understanding of the early phase of bipolar disorder, and to develop and evaluate effective psychosocial interventions that assist people in this phase.
- Conditions
- Mania, Hypomania, Bipolar Affective Disorder
- Trial name
- BISCIT (NCT01315028)
- Testing
- Cognitive Interpersonal Therapy, Treatment As Usual
- Where
- 2 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- NHS Greater Glasgow and Clyde
Major Depressive Disorder, Bipolar Disorder
Brain Mechanisms of Human Motivation
This study aims to investigate reward learning across the mood disorder spectrum and to investigate the predictive validity of reward learning for subsequent symptom severity.
- Trial name
- NCT01976975
- Where
- United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Bipolar Disorder
Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder
The purpose of the trial was to determine whether a 36-ingredient micronutrient supplement (primarily vitamins and minerals) is beneficial for the treatment of bipolar disorder, when studied under randomized and fully blinded…
- Trial name
- NCT00109577
- Testing
- MCN36 (nutritional supplement)
- Where
- 2 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- University of Calgary
Bipolar Disorder, Pediatric
Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)
Efficacy and safety of asenapine for the treatment of bipolar I disorder (manic or mixed episodes) will be evaluated in participants between 10 and 17 years old, who are either hospitalized or non-hospitalized.
- Trial name
- NCT01244815
- Testing
- asenapine, Rescue medication
- Volunteers
- 404 people
- Sponsor
- Organon and Co
Bipolar Disorder
Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder
This 26-week open-label extension study is designed to provide information on the safety and tolerability of oral ziprasidone (20-80 mg BID (twice daily) with meals) during long-term administration in children and adolescents…
- Trial name
- NCT03768726
- Testing
- Ziprasidone
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar Disorder, Schizoaffective Disorder
Probiotics to Prevent Relapse After Hospitalization for Mania
The purpose of this study is to determine if taking a probiotic supplement versus a placebo will lower rates of relapse and improve the clinical course among participants who have been hospitalized for mania.
- Trial name
- NCT01731171
- Testing
- Probiotic Supplement, Inert Compound
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Sheppard Pratt Health System